In 2024, global private equity and venture capital transaction value and volume in biotechnology declined to their lowest ...

CEO Tom Polen said BD will “double down on shifting our portfolio, both organically and inorganically through tuck-in M&A, into higher-growth, high-margin accretive growth spaces.” ...

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and ...

Parse Biosciences Inc. convinced an administrative tribunal to invalidate two 10x Genomics Inc. cell-analysis patents its products are accused of infringing. 10x sued Parse in August 2022 in the US ...

Business Wire IndiaParse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that the Patent Trial and Appeal Board (PTAB) of the United States ...

Important Information Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular ...

The European single cell multiomics market, valued at $527.9 million in 2021, is poised for significant growth, with projections indicating an annual growth rate of 18.0% over the decade from 2021 to ...

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and ...